Vitamin D and autoimmunity

Scandinavian Journal of Rheumatology

Volumn 45, Issue 6, 2016, Pages 439-447

  Rosen, Y ^a   Daich, J ^a   Soliman, I ^a   Brathwaite, E ^a   Shoenfeld, Y ^b  

^a State University of New York Health Science Center   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; CELIAC DISEASE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOMODULATION; MEDLINE; META ANALYSIS (TOPIC); MIXED CONNECTIVE TISSUE DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VITAMIN SUPPLEMENTATION; AUTOIMMUNE DISEASES; IMMUNE SYSTEM; IMMUNOLOGY; PHYSIOLOGY;

AUTOIMMUNE DISEASES; HUMANS; IMMUNE SYSTEM; VITAMIN D;

EID: 84994234534     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2016.1151072     Document Type: Review

References (109)

1. D.L.Kamen, V.Tangpricha Vitamin D and molecular actions on the immune system:modulation of innate and autoimmunity. J Mol Med (Berl) 2010;88:441–50.
2. B.W.Hollis. Assessment of vitamin D nutritional and hormonal status:what to measure and how to do it. Calcif Tissue Int 1996;58:4–5.
3. C.Aranow Vitamin D and the immune system. J Investig Med 2011;59:881–6.
4. E.Peelen, S.Knippenberg, A.H.Muris, M.Thewissen, J.Smolders, J.W.Tervaert, et al. Effects of vitamin D on the peripheral adaptive immune system:a review. Autoimmun Rev 2011;10:733–43.
5. H.F.DeLuca. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(Suppl 6):1689S–96S.
6. D.L.Longo, A.S.Fauci, D.L.Kasper, S.L.Hauser, J.L.Jameson, J.Loscalzo, eds. Harrison’s principles of internal medicine, 18th edn. New York, NY:McGraw-Hill, 2011.
7. S.Wu, S.Ren, L.Nguyen, J.S.Adams, M.Hewison. Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D3 production. Endocrinology 2007;148:3410–18.
8. E.Van Etten, K.Stoffels, C.Gysemans, C.Mathieu, L.Overbergh. Regulation of vitamin D homeostasis:implications for the immune system. Nutr Rev 2008;66(10 Suppl 2):S125–34.
9. A.Lleo, P.Invernizzi, B.Gao, M.Podda, M.E.Gershwin. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010;9:A259–66.
10. V.Molina, Y.Shoenfeld. Infection, vaccines and other environmental triggers autoimmunity. Autoimmunity 2005;38:235–45.
11. H.Orbach, G.Zandman- Goddard, H.Amital, V.Barak, Z.Szekanecz, G.Szucs, et al. Novel biomarkers in autoimmune diseases. Prolactin, ferritin, vitamin D and TPA levels in autoimmune diseases. Ann NY Acad Sci 2007;1109:385–400.
12. H.Orbach, Y.Shoenfeld. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007;6:537–42.
13. C.Perricone, N.Agmon-Levin, Y.Shoenfeld. Novel pebbles in the mosaic of autoimmunity. BMC Medicine 2013;11:101.
14. E.Ginanjar, S.S.Sumariyono, B.Setiyohadi. Vitamin D and autoimmune disease. Acta Med Indones 2007;39:133–41.
15. M.Z.Atassi, P.Casali. Molecular mechanisms of autoimmunity. Autoimmunity 2008;41:123–32.
16. S.Kivity, N.Agmon-Levin, M.Blank, Y.Shoenfeld. Infections and autoimmunity–friends or foes? Trends Immunol 2009;30:409–14.
17. M.Hewison. An update on vitamin D and human immunity. Clin Endocrinol (Oxf) 2012;76:315–25.
18. G.Bizzaro, Y.Shoenfeld. Vitamin D:a panacea for autoimmune diseases? Can J Physiol Pharmacol 2015;93:395–7.
19. Y.Arnson, H.Amital, Y.Shoenfeld. Vitamin D and autoimmunity:new etiological and therapeutical considerations. Ann Rheum Dis 2007;66:1137–42.
20. N.Shoenfeld, H.Amital, Y.Shoenfeld. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nature Rheumatol 2009;5:99–105.
21. M.F.Holick. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
22. Y.Shapira, N.Agmon-Levin, Y.Shoenfeld. Mycobacterium tuberculosis, autoimmunity, and Vitamin D. Clin Rev Allergy Immunol 2010;38:169–77.
23. A.R.Martineau, R.J.Wilkinson, K.A.Wilkinson, S.M.Newton, B.Kampmann, B.M.Hall, et al. A single dose of vitamin D enhanced immunity to mycobacteria. Am J Respir Crit Care Med 2007;176:208–13.
24. A.R.Martineau, S.Nhamoyebonde, T.Oni, M.X.Rangaka, S.Marais, N.Bangani, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci USA 2011;108:1913–17.
25. S.Joshi, L.C.Pantalena, X.K.Liu, S.L.Gaffen, H.Liu, C.Rohowsky-Kochan, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011;31:3653–69.
26. J.Tang, R.Zhou, D.Luger, W.Zhu, P.Silver, R.Grajewski, et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol 2009;182:4624–32.
27. L.Adorini, G.Penna. Control of autoimmune diseases by the vitamin D endocrine system. Nature Clin Pract Rheumatol 2008;4:404–12.
28. S.Gregori, N.Giarratana, S.Smiroldo, M.Uskokovic, L.Adorini. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002;51:1367–74.
29. M.R.Ardalan, H.Maljaei, M.M.Shoja, A.R.Piri, H.T.Khosroshahi, H.Noshad, et al. Calcitriol started in the donor, expands the population of CD4+ CD25+ T cells in renal transplant recipients. Transplant Proc 2007;39:951–3.
30. Z.Urry, E.Xystrakis, D.F.Richards, J.McDonald, Z.Sattar, D.J.Cousins, et al. Ligation of TLR9 induced on human IL-10 secreting Tregs by 1alpha,25 dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest 2009;119:387–9.
31. L.L.Ritterhouse, S.R.Crowe, T.B.Niewold, D.L.Kamen, S.R.Macwana, V.C.Roberts, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011;70:1569–74.
32. P.Gatenby, R.Lucas, A.Swaminathan. Vitamin D deficiency and risk for rheumatic diseases:an update. Curr Opin Rheumatol 2013;25:184–91.
33. L.L.Ishikawa, Y.Shoenfeld, A.Sartori. Immunomodulation in human and experimental arthritis:including vitamin D, helminths and heat-shock proteins. Lupus 2014;23:577–87.
34. G.Disanto, G.Chaplin, J.M.Morahan, G.Giovannoni, E.Hypponen, G.C.Ebers, et al. Month of birth, vitamin D and risk of immune mediated disease:a case control study. BMC Med 2012;10:69.
35. C.S.Zipitis, A.K.Akobeng. Vitamin D supplementation in early childhood and risk of type 1 diabetes:a systematic review and meta-analysis. Arch Dis Child 2008;93:512–17.
36. L.A.Merlino, J.Curtis, T.R.Mikuls, J.R.Cerhan, L.A.Criswell, K.G.Saag. Vitamin D intake is inversely associated with rheumatoid arthritis:results from the Iowa Women’s Health Study. Arthritis Rheum 2004;50:72–7.
37. M.Cutolo, K.Otsa, K.Laas, M.Yprus, R.Lehtme, M.E.Secchi, et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis:Northern versus Southern Europe. Clin Exp Rheumatol 2006;24:702–4.
38. G.S.Kerr, I.Sabahi, J.S.Richards, L.Caplan, G.W.Cannon, A.Reimold, et al. Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol 2011;38:53–9.
39. S.M.Craig, F.Yu, J.R.Curtis, G.S.Alarcón, D.L.Conn, B.Jonas, et al. Vitamin D status and its associations with disease activity and severity in African Americans with recent onset rheumatoid arthritis. J Rheumatol 2010;37:275–81.
40. C.C.Mok, D.J.Birmingham, H.W.Leung, L.A.Hebert, H.Song, B.H.Rovin. Vitamin D levels in Chinese patients with systemic lupus erythematosus:relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology (Oxford) 2012;51:644–52.
41. S.S.Yeap, A.Z.Othman, A.A.Zain, S.P.Chan. Vitamin D levels:its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids. Int J Rheum Dis 2012;15:17–24.
42. D.J.Birmingham, L.A.Hebert, H.Song, W.T.Noonan, B.H.Rovin, H.N.Nagaraja, et al. Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus 2012;21:855–64.
43. A.Vacca, C.Cormier, M.Piras, A.Mathieu, A.Kahan, Y.Allanore, et al. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol 2009;36:1924–9.
44. P.Caramaschi, A.Dalla Gassa, O.Ruzzenente, A.Volpe, V.Ravagnani, I.Tinazzi, et al. Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 2010;29:1419–25.
45. M.Soilu-Hänninen, L.Airas, I.Mononen, A.Heikkilä, M.Viljanen, A.Hänninen. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005;11:266–71.
46. T.Holmøy, Ø.Torkildsen, K.M.Myhr, K.I.Løken-Amsrud. Vitamin D supplementation and monitoring in multiple sclerosis:who, when and wherefore. Acta Neurol Scand 2012;(Suppl 195):63–9.
47. N.Stewart, S.SimpsonJr, I.van der Mei, A.L.Ponsonby, L.Blizzard, T.Dwyer, et al. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012;79:254–60.
48. K.L.Munger, L.I.Levin, B.W.Hollis, N.S.Howard, A.Ascherio Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832–8.
49. Y.Arnson, H.Amital, N.Agmon-Levin, D.Alon, M.Sánchez-Castañón, M.López-Hoyos, et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis:a retrospective cohort study and review of the literature. Autoimmun Rev 2011;10:490–4.
50. P.Humbert, J.L.Dupond, P.Agache, R.Laurent, A.Rochefort, C.Drobacheff, et al. Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3:evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol 1993;73:449–51.
51. M.M.Hulshof, S.Pavel, F.C.Breedveld, B.A.Dijkmans, B.J.Vermeer. Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994;130:1290–3.
52. N.G.Caca-Biljanovska, M.T.Vlckova-Laskoska, D.V.Dervendi, N.P.Pesic, D.S.Laskoski. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 1999;455:299–304.
53. E.F.Elst, L.W.Van Suijlekom-Smit, A.P.Oranje. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 1999;16:53–8.
54. M.M.Hulshof, J.N.Bouwes Bavinck, W.Bergman, A.A.Masclee, L.Heickendorff, F.C.Breedveld, et al. Double-blind, placebo controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000;43:1017–23.
55. Y.K.Tay. Topical calcipotriol ointment in the treatment of morphea. J Dermatolog Treat 2003;14:219–21.
56. B.B.Cunningham, I.D.Landells, C.Langman, D.E.Sailer, A.S.Paller. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998;39:211–15.
57. P.Zerr, S.Vollath, K.Palumbo-Zerr, M.Tomcik, J.Huang, A.Distler, et al. Vitamin D receptor regulates TGF-β signalling in systemic sclerosis. Ann Rheum Dis 2015;74:e20.
58. H.Amital, Z.Szekanecz, G.Szücs, K.Dankó, E.Nagy, T.Csépány, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity:is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010;69:1155–7.
59. Y.Schoindre, M.Jallouli, M.L.Tanguy, P.Ghillani, L.Galicier, O.Aumaître, et al. Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Sci Med 2014;1:e000027.
60. C.Aranow, D.L.Kamen, M.Dall’Era, E.M.Massarotti, M.C.Mackay, F.Koumpouras, et al. Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus. Arthritis Rheumatol 2015;67:1848–57.
61. L.Andreoli, F.Dall’Ara, S.Piantoni, A.Zanola, N.Piva, M.Cutolo, et al. A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus. Lupus 2015;24:499–506.
62. M.Petri, K.J.Bello, H.Fang, L.S.Magder. Vitamin D in systemic lupus erythematosus:modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum 2013;65:1865–71.
63. B.Terrier, N.Derian, Y.Schoindre, W.Chaara, G.Geri, N.Zahr, et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther 2012;14:R221.
64. A.Abou-Raya, S.Abou-Raya, M.Helmii. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus:a randomized placebo-controlled trial. J Rheumatol 2013;40:265–72.
65. P.Szodoray, I.F.Horvath, G.Papp, S.Barath, E.Gyimesi, L.Csathy, et al. The immunoregulatory role of vitamins A, D and E in patients with primary Sjogren’s syndrome. Rheumatology (Oxford) 2010;49:211–17.
66. K.Muller, P.Oxholm, O.H.Sorensen, M.Thymann, M.Hoier-Madsen, K.Bendtzen. Abnormal vitamin D3 metabolism in patients with primary Sjogren’s syndrome. Ann Rheum Dis 1990;49:682–4.
67. N.Agmon-Levin, S.Kivity, A.G.Tzioufas, M.López Hoyos, B.Rozman, I.Efes, et al. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren’s syndrome. J Autoimmun 2012;39:234–9.
68. T.Hickish, D.Cunningham, K.Colston, B.C.Millar, J.Sandle, A.G.Mackay, et al. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer 1993;68:668–72.
69. S.J.Kiraly, M.A.Kiraly, R.D.Hawe, N.Makhani. Vitamin D as a neuroactive substance:review. Sci World J 2006;6:125–39.
70. S.Skalli, M.Muller, S.Pradines, S.Halimi, N.Wion-Barbot. Vitamin D deficiency and peripheral diabetic neuropathy. Eur J Intern Med 2012;23:67–8.
71. S.Kivity, N.Agmon-Levin, M.Zisappl, Y.Shapira, E.V.Nagy, K.Dankó, et al. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol 2011;8:243–7.
72. G.Effraimidis, K.Badenhoop, J.G.Tijssen, W.M.Wiersinga. Vitamin D deficiency is not associated with early stages of thyroid autoimmunity. Eur J Endocrinol 2012;167:43–8.
73. J.Wang, S.Lv, G.Chen, C.Gao, J.He, H.Zhong. Meta-analysis of the association between vitamin D and autoimmune thyroid disease. Nutrients 2015;3:2485–98.
74. M.Feng, H.Li, S.F.Chen, W.F.Li, F.B.Zhang. Polymorphisms in the vitamin D receptor gene and risk of autoimmune thyroid diseases:a meta-analysis. Endocrine 2013;43:318–26.
75. N.Agmon-Levin, M.Blank, G.Zandman-Goddard, H.Orbach, P.L.Meroni, A.Tincani, et al. Vitamin D:an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011;70:145–50.
76. L.Andreoli, S.Piantoni, F.Dall’Ara, F.Allegri, P.L.Meroni, A.Tincani, et al. Vitamin D and antiphospholipid syndrome. Lupus 2012;21:736–40.
77. K.Klack, J.F.Carvalho. High frequency of vitamin D insufficiency in primary antiphospholipid syndrome. Joint Bone Spine 2010;77:489–90.
78. J.A.Paupitz, J.Freire De Carvalho, V.F.Caparbo, K.Klack, R.M.Pereira. Primary antiphospholipid syndrome in premenopausal women:low vitamin D, high fat mass and maintained bone mineral mass. Lupus 2010;19:1302–6.
79. S.Piantoni, L.Andreoli, F.Allegri, P.L.Meroni, A.Tincani. Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. Reumatismo 2012;64:307–13.
80. K.Ota, S.Dambaeva, A.R.Han, K.Beaman, A.Gilman-Sachs, J.Kwak-Kim. Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. Hum Reprod 2014;29:208–19.
81. M.J.Mulla, J.J.Brosens, L.W.Chamley, I.Giles, C.Pericleous, A.Rahman, et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol 2009;62:96–111.
82. S.M.Gysler, M.J.Mulla, M.Stuhlman, A.K.Sfakianaki, M.J.Paidas, N.L.Stanwood, et al. Vitamin D reverses aPL-induced inflammation and LMWH-induced sFlt-1 release by human trophoblast. Am J Reprod Immunol 2015;73:242–50.
83. A.Hajas, J.Sandor, L.Csathy, I.Csipo, S.Barath, G.Paragh, et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 2011;10:317–24.
84. A.Lerner, Y.Shapira, N.Agmon-Levin, A.Pacht, D.Ben-Ami Shor, H.M.López, et al. The clinical significance of 25OH-vitamin D status in celiac disease. Clin Rev Allergy Immunol 2012;42:322–30.
85. A.Tavakkoli, D.DiGiacomo, P.H.Green, B.Lebwohl. Vitamin D status and concomitant autoimmunity in celiac disease. J Clin Gastroenterol 2013;47:515–19.
86. M.Tsuji, K.Fujii, T.Nakano, Y.Nishii 1 alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett 1994;337:248–50.
87. T.Laragione, A.Shah, P.S.Gulko. The vitamin D receptor regulates rheumatoid arthritis synovial fibroblast invasion and morphology. Mol Med 2012;18:194–200.
88. Z.Andjelkovic, J.Vojinovic, N.Pejnovic, M.Popovic, A.Dujic, D.Mitrovic, et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999;17:453–6.
89. K.Gopinath, D.Danda. Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis:a randomised controlled trial. Int J Rheum Dis 2011;14:332–9.
90. M.Salesi, Z.Farajzadegan. Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy. Rheumatol Int 2012;32:2129–33.
91. K.E.Hansen, C.M.Bartels, R.E.Gangnon, A.N.Jones, J.Gogineni. An evaluation of high-dose vitamin D for rheumatoid arthritis. J Clin Rheumatol 2014;20:112–14.
92. M.Cutolo. Rheumatoid arthritis:circadian and circannual rhythms in RA. Nat Rev Rheumatol 2011;2:500–2.
93. G.Mouterde, C.Lukas, I.Logeart, R.M.Flipo, N.Rincheval, J.P.Daurès, et al. Predictors of radiographic progression in the ESPOIR cohort:the season of first symptoms may influence the short-term outcome in early arthritis. Ann Rheum Dis 2011;70:1251–6.
94. K.V.L Ng, L.T.Nguyễn. The role of vitamin d in primary biliary cirrhosis:possible genetic and cell signaling mechanisms. Gastroenterol Res Pract 2013;2013:602321.
95. A.Vogel, C.P.Strassburg, M.P.Manns. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002;35:126–31.
96. F.Canonne-Hergaux, S.Gruenheid, G.Govoni, P.Gros. The Nramp1 protein and its role in resistance to infection and macrophage function. Proc Assoc Am Physicians 1999;111:283–9.
97. V.Giacomet, A.Vigano, V.Manfredini, C.Cerini, G.Bedogni, S.Mora, et al. Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency:effects on vitamin D status and T-cell phenotype:a randomized controlled trial. HIV Clin Trials 2013;14:51–60.
98. M.E.Gershwin, Y.Shoenfeld, eds. Autoimmunity:Concepts and diagnosis at the cutting edge. Annals of the New York Academy of Sciences, volume 1050, Boston, MA:Wiley-Blackwell, 2005.
99. 3 (calcitriol). J Clin Invest 1984;74:1451–5.
100. J.M.Lemire, J.S.Adams, V.Kermani-Arab, A.C.Bakke, R.Sakai, S.C.Jordan. 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 1985;134:3032–5.
101. 3 inhibits γ-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1987;84:3385–9.
102. 3 on T lymphocyte subpopulations. Eur J Immunol 1987;17:563–6.
103. S.Scolletta, M.Colletti, L.Di Luigi, C.Crescioli. Vitamin D receptor agonists target CXCL10:new therapeutic tools for resolution of inflammation. Mediators Inflamm 2013;2013:876319.
104. Y.Chen, W.Liu, T.Sun, Y.Huang, Y.Wang, D.K.Deb, et al. 1,25 Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages. J Immunol 2013;190:3687–95.
105. O.Eyal, M.Aharon, R.Safadi, M.D.Elhalel. Serum vitamin D levels in kidney transplant recipients:the importance of an immunosuppression regimen and sun exposure. Isr Med Assoc J 2013;15:628–33.
106. Y.Oren, Y.Shapira, N.Agmon-Levin, S.Kivity, Y.Zafrir, A.Altman, et al. Vitamin D insufficiency in a sunny environment:a demographic and seasonal analysis. Isr Med Assoc J 2010;12:751–6.
107. J.P.Goff, N.J.Koszewski, J.S.Haynes, R.L.Horst. Targeted delivery of vitamin D to the colon using β-glucuronides of vitamin D:therapeutic effects in a murine model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2012;302:G460–9.
108. N.Binkley, R.Novotny, D.Krueger, T.Kawahara, Y.G.Daida, G.Lensmeyer, et al. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab 2007;92:2130–5.
109. C.D.Marques, A.T.Dantas, T.S.Fragoso, A.L.Duarte. The importance of vitamin D levels in autoimmune diseases. Rev Bras Rheumatol 2010;50:67–80.